HOMOLOGY MEDICINES INC (FIXX) Forecast, Price Target & Analyst Ratings
NASDAQ:FIXX • US4380831077
0.9347 USD
+0.01 (+0.77%)
At close: Mar 25, 2024
0.892 USD
-0.04 (-4.57%)
After Hours: 3/25/2024, 8:23:28 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HOMOLOGY MEDICINES INC (FIXX).
Forecast Snapshot
Consensus Price Target
$1.53
+ 63.69% Upside
Next Earnings Forecast
Release DateMay 9, 2024
PeriodQ1 / 2024
EPS Estimate-$0.23
Revenue Estimate
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.53
Upside
+ 63.69%
From current price of $0.93 to mean target of $1.53, Based on 6 analyst forecasts
Low
$1.52
Median
$1.53
High
$1.58
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for FIXX. The average price target is 1.53 USD. This implies a price increase of 63.69% is expected in the next year compared to the current price of 0.9347.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
FIXX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about FIXX.
In the previous month the buy percentage consensus was at a similar level.
FIXX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-07-28 | Baird | Downgrade | Outperform -> Neutral |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-05-12 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-03-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-17 | Chardan Capital | Maintains | Buy |
| 2022-11-11 | RBC Capital | Maintains | Sector Perform |
| 2022-08-31 | Baird | Maintains | Outperform |
| 2022-08-16 | Chardan Capital | Maintains | Buy |
| 2022-08-16 | BTIG | Maintains | Buy |
| 2022-08-16 | Credit Suisse | Maintains | Neutral |
| 2022-05-17 | Credit Suisse | Maintains | Neutral |
| 2022-04-28 | Credit Suisse | Initiate | Neutral |
| 2022-02-28 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-22 | Chardan Capital | Maintains | Buy |
| 2022-02-22 | BTIG | Maintains | Buy |
| 2022-02-22 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-02-22 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-02-22 | B of A Securities | Maintains | Buy |
| 2021-11-16 | Chardan Capital | Maintains | Buy |
| 2021-03-02 | Stifel | Initiate | Hold |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 9, 2024
PeriodQ1 / 2024
EPS Estimate-$0.23
Revenue Estimate
Revenue Q2Q-100.00%
EPS Q2Q53.08%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
FIXX is expected to report earnings on 5/9/2024. The consensus EPS estimate for the next earnings is -0.23 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 33.97M 1,158.15% | 3.21M -90.55% | 1.156M -63.99% | -100.00% | 2.04M | 2.04M | 2.04M | 2.04M | 350.88M 17,100.00% | 460.53M 31.25% | |
| EBITDA YoY % growth | -87.6M 28.37% | -131.99M -50.67% | -91.524M 30.66% | -147.457M -61.11% | -169.4M -14.88% | 32.538M 119.21% | 163.51M 402.52% | N/A | N/A | N/A | |
| EBIT YoY % growth | -95.95M 26.34% | -133.28M -38.91% | -92.102M 30.90% | -27.302M 70.36% | -41.31M -51.31% | -38.25M 7.41% | -35.19M 8.00% | -32.64M 7.25% | 70.89M 317.19% | 164.22M 131.65% | |
| Operating Margin | -282.46% | -4,152.02% | -7,967.30% | N/A | -2,025.00% | -1,875.00% | -1,725.00% | -1,600.00% | 20.20% | 35.66% | |
| EPS YoY % growth | -1.69 39.64% | -1.90 -12.43% | -1.96 -3.16% | -0.70 64.09% | -0.72 -1.59% | -1.31 -83.55% | -0.98 25.13% | -0.32 67.30% | 0.32 198.41% | 1.23 288.71% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.23 53.08% | -0.17 71.57% | -0.15 73.16% | -0.14 49.00% |
| Revenue Q2Q % growth | -100.00% | -100.00% | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.051M 63.46% | -6.556M 78.73% | -5.634M 76.87% | -5.062M 46.23% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
9.98%
EPS Next 5 Year
12.92%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
18.56%
Revenue Next 5 Year
10.76%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
32.15%
EBIT Next 5 Year
37.25%
HOMOLOGY MEDICINES INC / FIXX Forecast FAQ
What is the price target for FIXX stock?
6 analysts have analysed FIXX and the average price target is 1.53 USD. This implies a price increase of 63.69% is expected in the next year compared to the current price of 0.9347.
When does HOMOLOGY MEDICINES INC (FIXX) report earnings?
HOMOLOGY MEDICINES INC (FIXX) will report earnings on 2024-05-09, after the market close.
Can you provide the consensus estimates for HOMOLOGY MEDICINES INC next earnings?
The consensus EPS estimate for the next earnings of HOMOLOGY MEDICINES INC (FIXX) is -0.23 USD and the consensus revenue estimate is 0 USD.
Can you provide the expected long term growth rate for HOMOLOGY MEDICINES INC stock?
The expected long term growth rate for HOMOLOGY MEDICINES INC (FIXX) is 18.56%.